Why the study?
Are circulating sclerostin levels associated with cardiovascular mortality in individuals with and without type 2 diabetes?
Population
130 participants with and without type 2 diabetes
Design
Cohort
Authors
Loading...
Sclerostin may aid CV risk stratification in T2D; leaves open causal role and need for prospective validation before clinical use.
Are circulating sclerostin levels associated with cardiovascular mortality in individuals with and without type 2 diabetes?
High serum sclerostin levels are independently associated with cardiovascular mortality, suggesting its potential use as a novel biomarker for cardiovascular risk stratification.
Novo‐Rodríguez et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: